ライフサイエンスコーパス: salvage chemotherapy

1 patients may benefit more from conventional salvage chemotherapy.

2 patients may benefit more from conventional salvage chemotherapy.

3 al chemotherapy are potentially curable with salvage chemotherapy.

4 reated resection cavity (SCRC) and then with salvage chemotherapy.

5 poor predicted outcome to conventional-dose salvage chemotherapy.

6 able prognostic factors to conventional-dose salvage chemotherapy.

7 ell rescue (ASCT) compared with conventional salvage chemotherapy.

8 independent prognostic factors for PFS after salvage chemotherapy.

9 al BEP chemotherapy are usually treated with salvage chemotherapy.

10 e seminoma have resistant tumors and require salvage chemotherapy.

11 ve durable CR with conventional or high-dose salvage chemotherapy.

12 e, advanced, pure seminoma were treated with salvage chemotherapy.

13 ymphoma (NHL) after failures of standard and salvage chemotherapy.

14 f 24 (54%) are long-term survivors with VeIP salvage chemotherapy.

15 improves survival compared with conventional salvage chemotherapy.

16 d irradiation and five patients who received salvage chemotherapy.

17 , 24 patients were treated with conventional salvage chemotherapy, 14 patients were treated with high

18 nts experiencing relapse received successful salvage chemotherapy (4-year OS, 96%; 95% CI, 74% to 99%

19 High-dose chemotherapy as initial salvage chemotherapy achieved impressive long-term survi

20 ith relapsed or refractory lymphoma received salvage chemotherapy and were randomized to have HPC mob

21 one marrow transplantation rescue as initial salvage chemotherapy at Indiana University.

22 y best clinical response after completion of salvage chemotherapy (complete response vs partial respo

23 hat for non-HIV-cHL, and includes the use of salvage chemotherapy followed by autologous stem cell tr

24 sed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and a

25 itional cycles of standard-dose etoposide as salvage chemotherapy for germ cell tumors.

26 Salvage chemotherapy for recurrent chest wall lesions in

27 15 after primary chemotherapy and nine after salvage chemotherapy for relapsed HL.

28 5 micro g/kg (n = 33) in patients receiving salvage chemotherapy for relapsed or refractory Hodgkin'

29 otherapy (group A) and for 10 patients after salvage chemotherapy (group B).

30 side was first used at Indiana University as salvage chemotherapy in 1978, representing the first tim

31 ne therapy in early-stage breast cancer, and salvage chemotherapy in advanced ovarian cancer.

32 be the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma

33 yte colony-stimulating factor (G-CSF) (FLAG) salvage chemotherapy in patients with refractory or rela

34 on in a patient with head and neck cancer on salvage chemotherapy, including the epidermal growth fac

35 The benefit of salvage chemotherapy is modest in metastatic urothelial

36 Twenty-nine patients received salvage chemotherapy on a clinical trial for late relaps

37 It incorporates primary, adjuvant, and salvage chemotherapy, primary and post-chemotherapy RPLN

38 Cetuximab, used alone or with salvage chemotherapy, produces clinically meaningful ant

39 Because patients who undergo conventional salvage chemotherapy programs rarely achieve long-term d

40 age I EOC can be successfully treated with a salvage chemotherapy regimen after a policy of observati

41 latin-containing regimen were treated with a salvage chemotherapy regimen of ifosfamide, cisplatin, a

42 mor (FHWT) and recurrence after at least one salvage chemotherapy regimen or with anaplastic histolog

43 -C) is an essential component of primary and salvage chemotherapy regimens for acute myeloid leukemia

44 Salvage chemotherapy regimens integrating dose dense and

45 he leukemia burden prior to transplantation, salvage chemotherapy regimens need to be employed.

46 Eight of 34 patients (24%) who received salvage chemotherapy responded.

47 rmed indolent lymphoma (TRIL) often includes salvage chemotherapy (SC) and autologous stem cell trans

48 Eight patients underwent resection after salvage chemotherapy; six with histologic findings of ne

49 r, extranodal disease, and B symptoms before salvage chemotherapy (SLT) can stratify relapsed or refr

50 ose (FDG-PET) has not been established after salvage chemotherapy (ST) and before HDT-ASCT by modern

51 atients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-

52 sitive on positron emission tomography after salvage chemotherapy, the 16-month PFS was 0.70 (90% CI,

53 After three cycles of salvage chemotherapy, the responding patients received h

54 cally remain hospitalized after induction or salvage chemotherapy until blood cell count recovery, wi

55 cycles of bleomycin, etoposide, and platinum salvage chemotherapy was performed for five patients who

56 46 patients treated on a clinical trial with salvage chemotherapy was performed; 29 patients with lat

57 CR rates following salvage chemotherapy were 32% to 33% in the simultaneous

58 complete or very good partial remission with salvage chemotherapy were randomly assigned using a fact

59 or progressive disease at any time received salvage chemotherapy with cisplatin and etoposide.

60 e long-term survival and potential cure with salvage chemotherapy with paclitaxel plus gemcitabine af

61 cer patients will subsequently be cured with salvage chemotherapy with tandem transplant of high-dose